| Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models AS Leal, K Zydeck, S Carapellucci, LA Reich, D Zhang, JA Moerland, ... NPJ Breast Cancer 5 (1), 39, 2019 | 20 | 2019 |
| Potential therapeutic uses of rexinoids AS Leal, LA Reich, JA Moerland, D Zhang, KT Liby Advances in Pharmacology 91, 141-183, 2021 | 15 | 2021 |
| The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer JA Moerland, D Zhang, LA Reich, S Carapellucci, B Lockwood, AS Leal, ... Scientific Reports 10 (1), 22244, 2020 | 11 | 2020 |
| The RXR agonist MSU42011 Is effective for the treatment of preclinical HER2+ breast cancer and Kras-driven lung cancer AS Leal, JA Moerland, D Zhang, S Carapellucci, B Lockwood, ... Cancers 13 (19), 5004, 2021 | 10 | 2021 |
| The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer LA Reich, JA Moerland, AS Leal, D Zhang, S Carapellucci, B Lockwood, ... Scientific reports 12 (1), 293, 2022 | 8 | 2022 |
| The multi-faceted consequences of NRF2 activation throughout carcinogenesis CJ Occhiuto, JA Moerland, AS Leal, KA Gallo, KT Liby Molecules and cells 46 (3), 176-186, 2023 | 7 | 2023 |
| Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice D Zhang, B Singh, J Moerland, O Mitchell, L Lockwood, S Carapellucci, ... Scientific Reports 11 (1), 1234, 2021 | 6 | 2021 |
| The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner JA Moerland, AS Leal, B Lockwood, EY Demireva, H Xie, T Krieger-Burke, ... Antioxidants 12 (1), 116, 2023 | 4 | 2023 |
| The RXR agonist MSU-42011 and the MEK inhibitor selumetinib reduce pERK levels in NF1-deficient cells and inhibit cytokine production in macrophages PY Hung, JA Moerland, KT Liby Cancer Research 84 (6_Supplement), 2021-2021, 2024 | | 2024 |
| The triterpenoid CDDO-Methyl ester requires Nrf2 to decrease lung tumor burden and to protect against the toxicity of chemotherapy in experimental lung cancer JA Moerland, KT Liby Cancer Research 84 (6_Supplement), 2028-2028, 2024 | | 2024 |
| CDDO-methyl ester redirects macrophage polarization and reduces lung tumor burden in a Nrf2-dependent manner JA Moerland, KT Liby Cancer Research 83 (7_Supplement), 5176-5176, 2023 | | 2023 |
| The triterpenoid CDDO-Me redirects macrophage polarization and decreases tumor burden in a preclinical model of NSCLC JA Moerland, KT Liby Cancer Research 82 (12_Supplement), 3534-3534, 2022 | | 2022 |
| The novel rexinoid V-125 reduces tumor growth in the MMTV-Neu model of breast cancer and the A/J model of lung cancer via immunomodulation L Reich, J Moerland, AS Leal, D Zhang, S Carapellucci, CE Wagner, ... Cancer Research 82 (12_Supplement), 1118-1118, 2022 | | 2022 |
| Localized delivery of the PARP inhibitor Talazoparib for chemoprevention of breast cancer D Zhang, B Singh, J Moerland, O Mitchell, L Lockwood, S Carapellucci, ... Cancer Research 80 (16_Supplement), 12-12, 2020 | | 2020 |
